Tempest Therapeutics (TPST) said Thursday that the mid-stage clinical trial of TPST-1495 for the treatment of familial adenomatous polyposis has received a "study may proceed" letter from the US Food and Drug Administration.
The clinical-stage company said the Cancer Prevention Clinical Trials Network will run the mid-stage study, which will start this year and funded by the National Cancer Institute Division of Cancer Prevention.
Shares of the company were up more than 1% in recent premarket activity on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。